A Multi-centre, Open-label, Single-arm, Dose-finding Phase I/II Study to Evaluate Safety, Tolerability, Dosing Schedule, and Preliminary Efficacy of 131I-IPA, Administered in Patients With Recurrent GBM, Concomitantly With 2nd Line XRT
Phase of Trial: Phase I/II
Latest Information Update: 21 Aug 2019
Price : $35 *
At a glance
- Drugs ACD 101 (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- Acronyms IPAX-1
- Sponsors Telix Pharmaceuticals
- 08 Apr 2019 Status changed from not yet recruiting to recruiting.
- 25 Feb 2019 Planned initiation date changed from 11 Feb 2019 to 1 Mar 2019.
- 23 Feb 2019 Status changed to not yet recruiting.